Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVIDMAB: Sotrovimab PK in HCT Recipients
NCT05135650Phase 1Terminated
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Jan 2022
- Primary completion
- Oct 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sotrovimab in coronavirus disease 2019 (COVID-19), sponsored by Fred Hutchinson Cancer Center. Primary endpoints: Half-life of Sotrovimab (VIR-7831) Post-transplant at 24 weeks and Neutralizing Antibody Titers at 24 weeks. Started Jan 2022; status: terminated.
02
Drugs
sotrovimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05135650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05135650.